-
The top 15 pharma companies by 2014 revenueThe names at the very top of our yearly list of biggest pharma companies are no surprise. Johnson & Johnson ($JNJ), Novartis ($NVS), Roche ($RHHBY) and Pfizer ($PFE) have headed up the rankings fo2015/3/19
-
England's Cancer Drugs Fund changes its tune, holds onto Novartis' AfinitorIn the face of a backlash from drugmakers, England's Cancer Drugs Fund (CDF) is backtracking in its decision to remove certain treatments from its list of covered drugs. It has agreed to keep Novartis2015/3/19
-
China's drug approval backlog swells as it gets nearly 9,000 applications in 2014Western drugmakers have complained about how long it can take to get a drug approved for sale in China. Here is why,FiercePharmaAsiareports, citingReuters:Chinahad a backlog of more than 18,500 drugs2015/3/18
-
Hep C meds cost-effective, but affordable? With new 46% discounts, maybeWhenhepatitis Cdrugmakers started wooing payers with discounts, the cost cuts made the difference between an overwhelming burden and cost-effective spending. So say two new studies looking at the cost2015/3/18
-
Cost watchdogs back Novartis' Xolair for big new market in chronic hivesEngland's cost-effectiveness watchdogs have changed their mind on Xolair. The National Institute for Health and Care Excellence (NICE)decided to back the Novartis ($NVS) asthma drug as a treatment for2015/3/17
-
Cancer Drug Fund has failed, ex-health minister says: PMLiveEngland's Cancer Drugs Fund (CDF) is again under attack. The specialty fund has been getting it from both sides lately, as both drugmakers and cancer patients are upset over its deletion of coverage f2015/3/17
-
China's drug approval backlog swells as it gets nearly 9,000 applications in 2014Western drugmakers have complained about how long it can take to get a drug approved for sale in China. Here is why,FiercePharmaAsiareports, citingReuters:Chinahad a backlog of more than 18,500 drugs2015/3/16
-
CFDA releases 2014 Drug Review Annual ReportChina Food and Drug Administration (CFDA) recently released the 2014 Drug Review Annual Report. The Annual Report describes the general situation of drug registration acceptance, review and approval i2015/3/16
-
Pfizer hunts for new vaccines to protect young and oldPfizer is seeking new vaccine opportunities across the age spectrum as it broadens its portfolio by delivering shots into the arms of adolescents and the elderly, as well as infants. Previously relia2015/3/13
-
Docs, drugmakers conspire on lucrative new doses of old meds: NYTBehind the usual pharma scenes is a network ofdoctors, small drugmakers and distributors hawking new dosages of old drugs, a practice that allows physicians to dispense them and reap the profits by bi2015/3/12